Radiographic Findings in Patients with Medication-Related Osteonecrosis of the Jaw

Table 1

Data of 35 patients with MRONJ.

Patients	Age	Gender	Systemic disease	Bisphosphonate	Treatment (months)	Drug administration	Stage
1	45	Male	Cancer	Aredia	12	Intravenous	3
2	45	Male	Cancer	Zometa	20	Intravenous	0
3	54	Female	Cancer	Aredia/Zometa	84	Intravenous	0
4	42	Male	Cancer	Aredia	14	Intravenous	3
5	54	Female	Cancer	Zometa	28	Intravenous	1
6	52	Female	Cancer	Zometa	8	Intravenous	2
7	54	Female	Cancer	Zometa	108	Intravenous	2
8	68	Female	Osteoporosis	Fosamax	80	Oral	2
9	52	Female	Cancer	Zometa	48	Intravenous	1
10	49	Female	Cancer	Zometa	18	Intravenous	2
11	59	Female	Cancer	Zometa	8	Intravenous	1
12	39	Female	Cancer	Zometa	6	Intravenous	2
13	59	Female	Cancer	Aredia/Zometa	84	Intravenous	2
14	79	Female	Osteoporosis	Fosamax	56	Oral	2
15	52	Female	Cancer	Aredia	26	Intravenous	0
16	64	Female	Cancer	Zometa	30	Intravenous	2
17	74	Female	Cancer	Zometa	48	Intravenous	2
18	90	Female	Cancer	Zometa	12	Intravenous	2
19	57	Female	Cancer	Zometa	36	Intravenous	2
20	66	Female	Cancer	Zometa	36	Intravenous	2
21	64	Female	Cancer	Zometa	72	Intravenous	1
22	24	Male	Cancer	Zometa	18	Intravenous	1
23	77	Male	Cancer	Zometa	12	Intravenous	2
24	52	Male	Cancer	Zometa	22	Intravenous	1
25	65	Female	Cancer	Zometa	24	Intravenous	3
26	95	Female	Cancer	Bonviva	36	Oral	2
27	67	Female	Cancer	Zometa	288	Intravenous	2
28	58	Female	Cancer	Zometa	30	Intravenous	2
29	64	Female	Cancer	Zometa	6	Intravenous	0
30	50	Male	Cancer	Zometa	24	Intravenous	3
31	56	Female	Cancer	Zometa	24	Intravenous	1
32	64	Female	Cancer	Zometa	30	Intravenous	2
33	65	Female	Cancer	Zometa	48	Intravenous	2
34	60	Female	Cancer	Zometa	48	Intravenous	2
35	70	Male	Cancer	Zometa	16	Intravenous	1